Allakos Croissance future

Future contrôle des critères 0/6

Allakos devrait augmenter ses bénéfices et ses revenus de 15.7% et de 96.6% par an respectivement, tandis que le BPA devrait croître de croître de 31.7% par an.

Informations clés

15.7%

Taux de croissance des bénéfices

31.7%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.5%
Taux de croissance des recettes	96.6%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	07 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Is Allakos Inc. (NASDAQ:ALLK) Expensive For A Reason? A Look At Its Intrinsic Value

Jan 04

Allakos: Potential For Comeback With Lirentelimab With 2 Indications

Oct 18

Allakos prices ~$150M underwritten offering

Sep 19

Allakos falls as lead asset offers mixed results in late-stage trial

Sep 09

Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely

Aug 06

Will Allakos (NASDAQ:ALLK) Spend Its Cash Wisely?

Apr 22

Allakos: Sad End To A Promising Asset

Dec 23

We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely

Dec 01

We Think Allakos (NASDAQ:ALLK) Can Afford To Drive Business Growth

Aug 16

Allakos: Upcoming Phase 3 Data Makes The Stock Interesting

Aug 06

Allakos provides lirentelimab clinical trial enrollment updates, names new CMO

Jun 07

We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely

May 02

Have Allakos Inc. (NASDAQ:ALLK) Insiders Been Selling Their Stock?

Mar 10

Allakos Inc. (NASDAQ:ALLK) Insiders Have Been Selling

Jan 28

We're Interested To See How Allakos (NASDAQ:ALLK) Uses Its Cash Hoard To Grow

Dec 07

Allakos EPS misses by $0.02

Nov 09

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:ALLK - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	N/A	-85	N/A	-67	4
12/31/2025	N/A	-66	N/A	-20	5
12/31/2024	N/A	-130	N/A	-42	5
9/30/2024	N/A	-179	-105	-105	N/A
6/30/2024	N/A	-206	-103	-103	N/A
3/31/2024	N/A	-214	-119	-119	N/A
12/31/2023	N/A	-186	-117	-116	N/A
9/30/2023	N/A	-166	-140	-139	N/A
6/30/2023	N/A	-151	-139	-136	N/A
3/31/2023	N/A	-165	-142	-136	N/A
12/31/2022	N/A	-320	-288	-280	N/A
9/30/2022	N/A	-371	-322	-299	N/A
6/30/2022	N/A	-403	-350	-319	N/A
3/31/2022	N/A	-411	-371	-336	N/A
12/31/2021	N/A	-270	-241	-208	N/A
9/30/2021	N/A	-220	-195	-177	N/A
6/30/2021	N/A	-199	-174	-166	N/A
3/31/2021	N/A	-181	-143	-142	N/A
12/31/2020	N/A	-153	-115	-114	N/A
9/30/2020	N/A	-134	-99	-99	N/A
6/30/2020	N/A	-113	-79	-79	N/A
3/31/2020	N/A	-93	-69	-68	N/A
12/31/2019	N/A	-85	-64	-63	N/A
9/30/2019	N/A	-75	-60	-57	N/A
6/30/2019	N/A	-65	-55	-49	N/A
3/31/2019	N/A	-55	-49	-42	N/A
12/31/2018	N/A	-44	-45	-38	N/A
9/30/2018	N/A	-37	-38	-33	N/A
6/30/2018	N/A	-32	N/A	-30	N/A
3/31/2018	N/A	-27	N/A	-26	N/A
12/31/2017	N/A	-24	N/A	-23	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: ALLK devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: ALLK devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: ALLK devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: ALLK ne devrait pas générer de revenus l'année prochaine.

Croissance élevée des revenus: ALLK ne devrait pas générer de revenus l'année prochaine.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de ALLK devrait être élevé dans 3 ans

Allakos Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased by 32% to US$6.50

Price target decreased by 8.4% to US$9.08

Price target increased by 7.4% to US$8.67

Price target increased by 17% to US$8.50

Price target decreased by 19% to US$5.69

Price target increased to US$7.06

Recent updates

Allakos Runs Up Into A Near-Term Catalyst

Allakos Inc. Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers

We Think Allakos (NASDAQ:ALLK) Needs To Drive Business Growth Carefully

Allakos Inc. Receives A Letter from the Listing Qualifications Staff (The Staff") of the Nasdaq Stock Market LLC

New minor risk - Shareholder dilution

New major risk - Financial position

Allakos Inc.(NasdaqGS:ALLK) dropped from Russell Small Cap Comp Value Index

Allakos Inc. Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria

We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate

Allakos Inc., Annual General Meeting, May 24, 2024

New minor risk - Market cap size

CEO & Director notifies of intention to sell stock

Allakos Inc. Announces Publication Highlighting AK006 Mast Cell Inhibition

New minor risk - Market cap size

Allakos Announces Restructuring to Focus on Development of AK006

New major risk - Share price stability

Price target decreased by 32% to US$6.50

Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints

Price target decreased by 8.4% to US$9.08

CEO & Director notifies of intention to sell stock

We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate

Price target increased by 7.4% to US$8.67

CEO & Director notifies of intention to sell stock

Allakos Inc. Appoints Neil Graham to its Board of Directors

Allakos Inc. Announces Board Appointments

Allakos Inc. Announces Board of Directors Appointment

Companies Like Allakos (NASDAQ:ALLK) Are In A Position To Invest In Growth

CEO & Director notifies of intention to sell stock

Price target increased by 17% to US$8.50

Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely

Chief Medical Officer notifies of intention to sell stock

Price target decreased by 19% to US$5.69

Is Allakos Inc. (NASDAQ:ALLK) Expensive For A Reason? A Look At Its Intrinsic Value

CEO & Director notifies of intention to sell stock

Price target increased to US$7.06

Insufficient new directors

Price target increased to US$7.06

Allakos: Potential For Comeback With Lirentelimab With 2 Indications

Allakos prices ~$150M underwritten offering

Price target decreased to US$6.56

Allakos Inc. Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU)

Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis

Allakos falls as lead asset offers mixed results in late-stage trial

Price target decreased to US$7.11

Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely

Allakos Inc. Announces the Appointment of Dr. Amy Ladd to Its Board of Directors

Allakos Inc.(NasdaqGS:ALLK) dropped from Russell 2000 Growth Index

Price target decreased to US$10.28

Insufficient new directors

Will Allakos (NASDAQ:ALLK) Spend Its Cash Wisely?

Allakos Inc. Announces Management Changes

Allakos Inc., Annual General Meeting, May 25, 2022

Allakos Inc. to Hold an End-Of-Phase 2 Meeting with the FDA During Second Quarter of 2022

Price target decreased to US$19.38

Allakos: Sad End To A Promising Asset

Price target decreased to US$51.44

Allakos Inc. Announces Topline Phase 3 Data from the ENIGMA 2 Study and Phase 2/3 Data from the KRYPTOS Study in Patients with Eosinophilic Gastrointestinal Diseases

Allakos Inc. Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma

We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely

Independent Director exercised options and sold US$430k worth of stock

President & COO exercised options to buy US$6.2m worth of stock.

We Think Allakos (NASDAQ:ALLK) Can Afford To Drive Business Growth

Allakos Provides Business Update

Allakos: Upcoming Phase 3 Data Makes The Stock Interesting

Insufficient new directors

President & COO exercised options and sold US$3.6m worth of stock

CEO & Director exercised options and sold US$4.0m worth of stock

CEO & Director recently sold US$2.0m worth of stock

Allakos Inc. Completes Enrollment in Phase 3 Study of Lirentelimab in Patients with Eosinophilic Gastritis